CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

Update: 2024-07-31

Description

Novel Psychedelics drug developer Cybin's CEO Doug Drydale joins WTR's Tim Gerdman and Robert Sassoon to talk about the company's fast-track development into a late-stage clinical development company, and what differentiates Cybin from other drug developers in the psychedelics space. Drysdale discusses Cybin's plans and priorities for its development pipeline going forward and talks about the company's extensive IP real estate. He also shares his perspectives on the regulatory uncertainty currently surrounding Lykos's MDMA-AT and how Cybin is dealing with it to its benefit

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

1-800-FLOWERS.COM Initiation of Coverage Review: Building a Pre-Eminent E-Commerce Gifting Platform

2024-09-2009:17

Gevo Initiation of Coverage Review: Delivering Carbon Abatement with Renewable Fuels and Technologies as Cost Effectively as Possible

2024-09-1921:01

Unusual Machines (UMAC) CEO Dr. Allan Evans Highlights Regulatory Changes Driving US Drone Market

2024-09-1823:47

The Future of Industrial IoT: AI, Network Resilience, and Data Center Evolution with Opengear's Patrick Quirk

2024-08-2828:01

On the Frontlines of Cybersecurity with Digital Executive Protection at BlackCloak

2024-08-1417:14

Water Tower Research unveils rebranded podcast series, now called WTR Small-Cap Spotlight

2024-08-0713:20

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

2024-07-3120:45

Ainos Inc. Director of Corporate Development Jack Lu on AI Nose Platform

2024-07-2418:04

Gorilla Technology IOC Discussion with WTR's President Shawn Severson and Technology Analyst Dr. John Roy

2024-07-1909:53

Aspira Women’s Health CEO Nicole Sandford on OvaWatch Progress and Recent Financing

2024-07-1735:50

An Introduction to CLS Holdings with COO Joseph Ramalho and WTR’s Jesse Redmond

2024-07-1632:18

111 Inc IoC Review - A Leader in the Digital Transformation of China’s Healthcare Supply Chain

2024-07-1216:42

Arq, Inc. CEO Bob Rasmus on the transformation of the company and the outlook for growth in new markets

2024-07-1020:42

Envoy Medical – Developing a Disruptive Fully Implanted Cochlear Implant for Patients with Severe Hearing Loss

2024-07-0231:57

Consumer Products Conference Recap : Resumption of Top-Line Growth Could Be a Powerful Catalyst

2024-06-2718:22

Spruce Power IOC Review – Competitive Servicing "Moat" Supports Residential Rooftop Solar Acquisition Strategy

2024-06-2511:34

Ainos Initiation of Coverage Review – AI Nose Tech and Veldona Drug in Pipeline

2024-06-2413:06

Canadian Climate Investor Conference Preview / Outlooks for Voluntary Carbon and Solar Markets

2024-06-2029:59

Recapping the 2024 Louisiana Energy Conference and Looking Ahead to 2025

2024-06-1222:18

Cody Shandraw – An Investor’s Perspective on the Psychedelics Landscape

2024-06-0537:48

00:00

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

#box-pro-ellipsis-172697585112531{-webkit-line-clamp:2;}CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

Water Tower Research

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need